MLNT - MLNT Stock Moves Up Big On FDA Boost: Baxdela sNDA
MLNT stock more than tripled following Melinta Therapeutics Inc (NASDAQ:MLNT) announcing that its supplemental New Drug Application (sNDA) for Baxdela was approved by the FDA.
Big Day for MLNT StockConnecticut-based Melinta Therapeutics, which is involved in the development and marketing of antibiotics meant for the treatment of bacterial infections, received a major boost today from the United States Food and Drug Administration.
In a new development, the company’s supplemental New Drug Application (sNDA) for the product named Baxdela has been permitted a priority review, and as everyone knows, this is a significant milestone ...
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.